Type III secretion system-associated toxins, proteases, serotypes, and antibiotic resistance of Pseudomonas aeruginosa isolates associated with keratitis

Current Eye Research

Volumn 31, Issue 4, 2006, Pages 297-306

  Zhu, Hua ^a   Conibear, Tim C R ^a   Bandara, Rani ^a   Aliwarga, Yulina ^a   Stapleton, Fiona ^a   Willcox, Mark D P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antibiotic resistance; Proteases; Pseudomonas aeruginosa; Serotypes; Type III secretion toxins

Indexed keywords

CIPROFLOXACIN; CYTOTOXIN; PROTEINASE; TOXIN;

ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRALIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYTOTOXICITY; DISEASE ASSOCIATION; INDIA; KERATITIS; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEROTYPE; STATISTICAL SIGNIFICANCE;

ADP RIBOSE TRANSFERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXINS; DRUG RESISTANCE; EYE INFECTIONS, BACTERIAL; GENES, BACTERIAL; GENOTYPE; HUMANS; KERATITIS; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; SERINE ENDOPEPTIDASES;

EID: 33645788858     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500536746     Document Type: Article

References (56)

1. Holden BA, La Hood D, Grant T, et al. Gram-negative bacteria can induce contact lens related acute red eye (CLARE) responses. CLAO J. 1996;22:47-52.
2. Laibson PR, Donnenfeld ED. Corneal ulcers related to contact lens use. In: Cohen, EJ, Contact Lenses and External Disease. Boston: Little, Brown & Company, 1986:3-14.
3. Cheng K, Leung D, Hoekman H, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet. 1999;354:181-184.
4. Kang PJ, Hauser AR, Apodaca G, et al. Identification of Pseudomonas aeruginosa genes required for epithelial cell injury. Mol Microbiol. 1997;24:1249-1262.
5. Yahr TL, Mende-Mueller LM, Friese MB, Frank DW. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon. J. Bacteriol. 1997;179:7165-7168.
6. Frank DW. The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol. 1997;26:621-629.
7. Frithz-Lindsten E, Du Y, Rosqvist R, Forsberg A. Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments. Mol Microbiol. 1997; 25:1125-1139.
8. Finck-Barbancon V, Goranson J, Zhu L, et al. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol. 1997;25:547-557.
9. Hauser AR, Kang PJ, Engel JN. PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence. Mol Microbiol. 1998;27:807-818.
10. Yahr TL, Vallis AJ, Hancock MK, et al. ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Nat Acad Sci USA. 1998;95:13899-13904.
11. Fleiszig SM, Wiener-Kronish JP, Miyazaki H, et al. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infec Immun. 1997;65:579-586.
12. Coburn J, Frank DW. Macrophages and epithelial cells respond differently to the Pseudomonas aeruginosa type III secretion system. Infec Immun. 1999;67:3151-3154.
13. Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Criti Care Medi. 2002;30:521-528.
14. Roy-Burman A, Savel RH, Racine S, et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis. 2001;183:1767-1774.
15. Fleiszig SM, Lee EJ, Wu C, et al. Cytotoxic strains of Pseudomonas aeruginosa can damage the intact corneal surface in vitro. CLAO J. 1998;24:41-47.
16. Zhu H, Thuruthyil SJ, Willcox MDP. Determination of quorum-sensing signal molecules and virulence factors of Pseudomonas aeruginosa strains isolated from contact lens-induced microbial keratitis. J Med Microbiol. 2002;51:1063-1070.
17. Cole N, Willcox MD, Fleiszig SM, et al. Different strains of Pseudomonas aeruginosa isolated from ocular infections or inflammation display distinct corneal pathologies in an animal model. Curr Eye Res. 1998;17:730-735.
18. Cowell BA, Willcox MD, Hobden JA, et al. An ocular strain of Pseudomonas aeruginosa is inflammatory but not virulent in the scarified mouse model. Exp Eye Res. 1998;67:347-356.
19. Morihara K, Homma JY. Pseudomonas Proteases. Boca Raton, FL:CRC Press Inc., 1985.
20. Caballero A, Thibodeaux B, Marquart M, et al. Pseudomonas keratitis:Protease IV gene conservation, distribution, and production relative to virulence and other Pseudomonas proteases. Invest Ophthalmol Visual Sci. 2004;45:522-530.
21. Bower KS, Kowalski RP, Gordon YJ. Fluoroquinolones in the treatment of bacterial keratitis. Am J Ophthalmol. 1996;121:712-715.
22. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol. 1995;113:1257-1265.
23. Chaudhry NA, Flynn HW, Murray TG, et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999;128:(4):509-510.
24. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:8:1497-1502.
25. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999;106:1319-1323.
26. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999;106:80-85.
27. Tassios PT, Gennimata V, Maniatis AN, et al. Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. J Clin Microbiol. 1998;36:897-901.
28. Bouza E, Garcia-Garrote F, Cercenado E, et al. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain. Antimicrob Agents Chemother. 1999; 43:981-982.
29. Thuruthyil SJ, Zhu H, Willcox MDP. Serotype and adhesion of Pseudomonas aeruginosa isolated from contact lens wearers. Clin Exp Ophthalmol. 2001;29:147-149.
30. Berthelot P, Attree I, Plesiat P, et al. Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates:evidence for a possible association between O serotypes and exo genes. J. Infect Dis. 2003; 188:512-518.
31. Faure K, Shimabukuro D, Ajayi T, et al. O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa. J Clin Microbiol. 2003; 41:2158-2160.
32. Lakkis C, Fleiszig SMJ. Resistance of Pseudomonas aeruginosa isolates to hydrogel contact lens disinfection correlates with cytotoxic activity. J Clin Microbiol. 2001;39:1477-1486.
33. Allewelt M, Coleman FT, Grout M, et al. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infec Immun. 2000; 68:3998-4004.
34. Lomholt JA, Poulsen K, Kilian M. Epidemic population structure of Pseudomonas aeruginosa:Evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors. Infect. Immun. 2001;69:6284-6295.
35. Bell SM, Gatus BJ, Pham JN. Antibiotic Susceptibility Testing by the CDS Methods:A Concise Laboratory Manual. South Eastern Area Laboratory Services, Sydney, Australia; 1999.
36. Cowell BA, Weissman BA, Yeung KK, et al. Phenotype of Pseudomonas aeruginosa isolates causing corneal infection between 1997 and 2000. Cornea 2003;22:131-134.
37. Winstanley C, Kaye SB, Neal TJ, et al. Genotypic and phenotypic characteristics of Pseudomonas aeruginosa isolates associated with ulcerative keratitis. J Med Microbiol. 2005;54:519-526.
38. Fleiszig SM, Zaidi TS, Preston MJ, et al. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun. 1996;64:2288-2294.
39. Feltman H, Schulert G, Khan S, et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001;147:2659-2669.
40. Dacheux D, Toussaint B, Richard M, et al. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils. Infec Immun. 2000;68:2916-2924.
41. Woods DE, Sokol PA. Role of Pseudomonas aeruginosa extracellular enzymes in lung disease. Clin Investi Medi Medecine Clinique et Experimentale. 1986;9:108-112.
42. Rumbaugh KP, Griswold JA, Hamood AN. Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection:variations in virulence factors and virulence genes. J. Hosp Infect. 1999;43:211-218.
43. Schulert GS, Feltman H, Rabin SD, et al. Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infec Dis. 2003;188:1695-1706.
44. Cowell BA, Twining SS, Hobden JA, et al. Mutation of lasA and lasB reduces Pseudomonas aeruginosa invasion of epithelial cells. Microbiology. 2003;149:2291-2299.
45. Zhu H, Bandara R, Conibear TCR, Kjelleberg S et al. Pseudomonas aeruginosa with lasI quorum-sensing deficiency during corneal infection. Invest Ophthalmo Vis Sci. 2004;45:1897-1903.
46. Zhu H, Thuruthyil SJ, Willcox MDP. Contribution of quorum-sensing systems to the virulence of Pseudomonas aeruginosa during corneal infections. Invest Ophthalmol Vis Sci 2001;42:S514.
47. Hummel KM, Penheiter AR, Gathman AC, Lilly WW. Anomalous estimation of protease molecular weights using gelatin-containing SDS-PAGE. Anal Biochem. 1995;233:140-142.
48. Raymond CK, Sims EH, Kas A, et al. Genetic variation at the O-antigen biosynthetic locus in Pseudomonas aeruginosa. J Bacteriol. 2002;184:3614-3622.
49. Farmer JJr, Weinstein RA, Zierdt CH, Brokopp CD. Hospital outbreaks caused by Pseudomonas aeruginosa:Importance of serogroup O11. J Clin Microbiol. 1982;16:266-270.
50. Elder MJ, Morlet N. Endophthalmitis. Clin Expe Ophthalmo. 2002;30:394-398.
51. Leibovitch I, Lai TF, Senarath L, et al. Infectious keratitis in South Australia:Emerging resistance to cephazolin. Eur J Ophthalmol. 2005;15:23-26.
52. Kucers A, Crowe SM, Grayson ML, Hoy JF. The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 5th ed. Oxford:Butterworth-Heinemann; 1997.
53. Rhee MK, Kowlski RP, Romanowski EG, et al. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Ame J Ophthalmo. 2004;138:226-230.
54. Robinson A, Kremer I, Avisar R, et al. The combination of topical ceftazidime and aminoglycosides in the treatment of refractive pseudomonal keratitis. Graefes Arch Clin Expe Ophthalmol. 1999;237:177-180.
55. Lee EJ, Truong TN, Mendoza MN, Fleiszig SMJ. A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics. Curr Eye Res. 2003;27:289-299.
56. Marquart ME, Caballero AR, Chomnawang M, et al. Identification of a novel secreted protease from Pseudomonas aeruginosa that causes corneal erosions Inves Ophthalmol Visi Sci. 2005;46:3761-3768.